In this article, we will discuss Alectinib (Dosage Overview). So, let’s get started.
Alectinib as monotherapy is indicated for the first-line treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC). Alectinib as monotherapy is indicated for the treatment of adult patients with ALK-positive advanced NSCLC previously treated with crizotinib.
Treatment with Alectinib should be initiated and supervised by a physician experienced in the use of anticancer medicinal products.
A validated ALK assay is necessary for the selection of ALK-positive NSCLC patients. ALK-positive NSCLC status should be established prior to initiation of Alectinib therapy.
The recommended dose of Alectinib is 600 mg (four 150 mg capsules) taken twice daily with food (total daily dose of 1200 mg).
Patients with underlying severe hepatic impairment (Child-Pugh C) should receive a starting dose of 450 mg taken twice daily with food (total daily dose of 900 mg).
Duration of treatment
Treatment with Alectinib should be continued until disease progression or unacceptable toxicity.
Management of adverse events may require dose reduction, temporary interruption, or discontinuation of treatment with Alectinib. The dose of Alectinib should be reduced in steps of 150 mg twice daily based on tolerability. Alectinib treatment should be permanently discontinued if patients are unable to tolerate the 300 mg twice daily dose.